Definition

A combination of nivolumab and relatlimab used to treat adults and children aged 12 years or older with melanoma that has spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Opdualag binds to the proteins PD-1 and LAG-3, which are found on T cells (a type of immune cell). Blocking these proteins may help the immune system kill cancer cells. The combination of nivolumab and relatlimab may work better than either drug alone. Opdualag is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called nivolumab and relatlimab.